Drug Profile
Selinexor- Karyopharm Therapeutics
Alternative Names: ATG-010; CRM1-nuclear-export-inhibitor; KPT-330; NEXPOVIO; ONO 7705; Selinisso; TP-53; XPOVIOLatest Information Update: 22 Mar 2024
Price :
$50
*
At a glance
- Originator Karyopharm Therapeutics
- Developer Antengene Corporation; Cardiff University; Grupo Espanol de Investigacion en Sarcomas; Karyopharm Therapeutics; Menarini; Ono Pharmaceutical; Promedico; University of Texas Southwestern Medical Center
- Class Acrylamides; Anti-infectives; Antineoplastics; Antivirals; Fluorinated hydrocarbons; Foot disorder therapies; Hydrazines; Pyrazines; Small molecules; Triazoles
- Mechanism of Action Exportin-1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Diffuse large B cell lymphoma; Multiple myeloma
- Phase III Endometrial cancer; Liposarcoma; Myelofibrosis
- Phase II/III Acute myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Phase II Colorectal cancer; COVID 2019 infections; Malignant melanoma; Ovarian cancer; Peripheral T-cell lymphoma; Thymic epithelial tumour; Thymoma; Triple negative breast cancer
- Phase I/II Gastrointestinal stromal tumours; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours
- Phase I Liver cancer
- Preclinical Sepsis
- No development reported B-cell lymphoma; Cervical cancer; Chronic lymphocytic leukaemia; Extranodal NK-T-cell lymphoma; Glioma; HER2 positive breast cancer; Neuroendocrine tumours; Osteosarcoma; Soft tissue sarcoma
- Discontinued Cutaneous T-cell lymphoma; Diabetic foot ulcer; Gastric cancer; Glioblastoma; Oesophageal cancer; Prostate cancer; Rectal cancer; Richter's syndrome; Small cell lung cancer; Squamous cell cancer
Most Recent Events
- 22 Mar 2024 Karyopharm Therapeutics plans a phase II trial in Myelofibrosis and Thrombocytopenia (Monotherapy, Treatment naïve) (PO, tablet) in March 2024 (NCT05980806)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Osteosarcoma(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain (PO, Tablet)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Soft tissue sarcoma(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain (PO, Tablet)